Drug-Drug Interactions Involving Antidepressants: Focus on Venlafaxine

Journal of Clinical Psychopharmacology

Volumn 16, Issue 3 SUPPL. 2, 1996, Pages

  Ereshefsky, Larry ^a,b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; FLUOXETINE; ISOENZYME; PAROXETINE; VENLAFAXINE;

CONSTIPATION; DEPRESSION; DRUG EFFICACY; DRUG INTERACTION; DRUG SAFETY; HUMAN; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOMNOLENCE; SWEATING; VERTIGO; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSIVE DISORDER; DRUG INTERACTIONS; HUMANS; ISOENZYMES; LIVER; SEROTONIN UPTAKE INHIBITORS;

EID: 0029951845     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199606002-00009     Document Type: Article

References (21)

1. Brosen K. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet 1990;18:220-39.
2. DeVane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry 1994;55[suppl 12]:38-45.
3. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
4. Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994;26:144-60.
5. Guengerich FP. Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity. Toxicol Lett 1994;70:133-8.
6. Strobel HW, Hodgson AV, Shen S. NADPH cytochrome P450 reductase and its structural and functional domains. In: Ortiz de Montellano PR, ed. Cytochrome P450: structure, mechanism, and biochemistry. 2nd ed. New York: Plenum Press, 1995:225-44.
7. Lin K-M, Poland RE. Ethnicity, culture and psychopharmacology. Psychiatr Times 1995;12(3):20-4.
8. Coutts RT. Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping. J Psychiatry Neurosci 1994;19:30-14.
9. von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI. Cytochromes in psychopharmacology [editorial]. J Clin Psychopharmacol 1994;14:1-4.
10. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
11. Hamelin BA, Turgeon J, Vallee F, Belanger P-M, Paquet F, LeBel M. Role of CYP2D6 in the demethylation of fluoxetine in vivo. From the proceedings of the 97th annual meeting of the American Society for Clinical Pharmacology and Therapeutics. Orlando, FL: March 22, 1996. Abstract PI-33, p. 137.
12. Guengerich FP. Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, ed. Cytochrome P450: structure, mechanism, and biochemistry. 2nd ed. New York: Plenum Press, 1995:473-535.
13. Ereshefsky L, Riesenman C, Lam YWF. Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. J Clin Psychiatry 1996;57[suppl], in press.
14. Riesenman C. Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. Pharmacotherapy 1995;15(6 Pt 2):84S-99S.
15. Ketter TA, Flockhart DA, Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, George MS, Callahan AM. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995;15:387-98.
16. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, Gotoh O, Okuda K, Nebert DW. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993;12:1-51.
17. Nebert DW, Adesnik M, Coon MJ, Estabrook RW, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, Kemper B, Levin W, Phillips IR, Sato R, Waterman MR. The P450 gene superfamily: recommended nomenclature. DNA 1987;6:1-11.
18. Preskorn SH, Magnus RD. Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharmacol Bull 1994;30:251-9.
19. Ciummo PE, Katz NL. Interactions and drug-metabolizing enzymes. Am Pharm 1995;NS35:41-53.
20. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-84.
21. Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 1993;54:463-72.